Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Diageo FY operating profits slump, organic net sales grow

(Sharecast News) - Alcoholic beverage giant Diageo posted a mixed set of FY results on Tuesday, as the group navigated FX headwinds and restructuring costs while maintaining organic growth. Organic net sales rose 1.7%, supported by balanced volume and pricing gains, while operating profits before exceptional items dipped just 0.7% to $5.7bn, reflecting continued investment in overheads, while adjusted margins narrowed 68 basis points to 28.2%.

However, reported earnings were impacted by impairment charges and FX effects, with operating profits down 27.8% at $4.33bn, reported net profit 39.1% lower at $2.53bn, and basic EPS down 38.9% at USD 105.9 cents.

Cash generation remained strong, with free cash flow rising to $2.74bn and net operating cash flow topping $4.3bn, up from $2.33bn and $4.1bn, respectively. Diageo also increased its cost savings target under its Accelerate programme to $625m and expects to deliver $3bn in free cash flow in fiscal 2026.

Diageo said its diversified portfolio and disciplined execution helped offset pressure across parts of its business, with standout performances from the Don Julio, Guinness, and Crown Royal Blackberry brands.

It also recommended a FY dividend of USD 103.48 cents.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.